Literature DB >> 27905175

Racial disparity in all-cause mortality among hepatitis C virus-infected individuals in a general US population, NHANES III.

B Emmanuel1, M D Shardell2, L Tracy3,4, S Kottilil1, S S El-Kamary3.   

Abstract

There are few long-term nationally representative studies of all-cause mortality among those infected with hepatitis C virus (HCV). When an additional 5 years of data were made publicly available in 2015, the Third National Health and Nutrition Examination Survey Linked Mortality File became the longest nationally representative study in the United States. Our objective was to update the estimated HCV-associated all-cause mortality in the general US population and determine any differences by sex, age and race/ethnicity. HCV status was assessed in 9117 nationally representative adults aged 18-59 years from 1988 to 1994, and mortality follow-up of the same individuals was completed through 2011 and made publicly available in 2015. There were 930 deaths over a median follow-up of 19.8 years. After adjusting for all covariate risk factors, chronic HCV had 2.63 times (95% CI: 1.59-4.37; P=.0002) higher all-cause mortality rate ratio (MRR) compared with being HCV negative. All-cause MRR was stratified by sex, age and race/ethnicity. Only race/ethnicity was a significant effect modifier of MRR (P<.0001) as the highest MRR of chronic HCV compared to HCV negative was 7.48 (95% CI: 2.15-26.10, P=.001) among Mexican Americans, 2.67 (95% CI: 2.67-5.56, P=.009) among non-Hispanic Whites and 2.02 (95% CI: 1.20-3.40, P=.007) among non-Hispanic Blacks. Racial disparity was seen in the all-cause mortality as Mexican Americans with chronic HCV had approximately seven times higher mortality rate than HCV-negative individuals. This suggests that these at-risk individuals should be targeted for HCV screening and treatment, given the availability of new highly effective HCV therapies.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  Mexican Americans; hepatitis C virus; mortality; racial disparity

Mesh:

Year:  2016        PMID: 27905175      PMCID: PMC5739320          DOI: 10.1111/jvh.12656

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  22 in total

1.  Sample design: Third National Health and Nutrition Examination Survey.

Authors:  T M Ezzati; J T Massey; J Waksberg; A Chu; K R Maurer
Journal:  Vital Health Stat 2       Date:  1992-09

2.  Disparity in liver cancer incidence and chronic liver disease mortality by nativity in Hispanics: The Multiethnic Cohort.

Authors:  Veronica Wendy Setiawan; Pengxiao C Wei; Brenda Y Hernandez; Shelly C Lu; Kristine R Monroe; Loic Le Marchand; Jian Min Yuan
Journal:  Cancer       Date:  2016-02-24       Impact factor: 6.860

3.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.

Authors:  M J Alter; D Kruszon-Moran; O V Nainan; G M McQuillan; F Gao; L A Moyer; R A Kaslow; H S Margolis
Journal:  N Engl J Med       Date:  1999-08-19       Impact factor: 91.245

4.  Hepatitis C in the United States.

Authors:  Scott D Holmberg; Philip R Spradling; Anne C Moorman; Maxine M Denniston
Journal:  N Engl J Med       Date:  2013-05-16       Impact factor: 91.245

Review 5.  Treatment of hepatitis C: a systematic review.

Authors:  Anita Kohli; Ashton Shaffer; Amy Sherman; Shyam Kottilil
Journal:  JAMA       Date:  2014-08-13       Impact factor: 56.272

6.  Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes.

Authors:  Hamish A Innes; Scott A McDonald; John F Dillon; Sam Allen; Peter C Hayes; David Goldberg; Peter R Mills; Stephen T Barclay; David Wilks; Heather Valerio; Ray Fox; Diptendu Bhattacharyya; Nicholas Kennedy; Judith Morris; Andrew Fraser; Adrian J Stanley; Peter Bramley; Sharon J Hutchinson
Journal:  Hepatology       Date:  2015-03-25       Impact factor: 17.425

7.  Hepatitis C testing, infection, and linkage to care among racial and ethnic minorities in the United States, 2009-2010.

Authors:  Rania A Tohme; Jian Xing; Youlian Liao; Scott D Holmberg
Journal:  Am J Public Health       Date:  2012-11-15       Impact factor: 9.308

8.  Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States.

Authors:  Sean F Altekruse; S Jane Henley; James E Cucinelli; Katherine A McGlynn
Journal:  Am J Gastroenterol       Date:  2014-02-11       Impact factor: 10.864

9.  Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

Authors:  Adriaan J van der Meer; Bart J Veldt; Jordan J Feld; Heiner Wedemeyer; Jean-François Dufour; Frank Lammert; Andres Duarte-Rojo; E Jenny Heathcote; Michael P Manns; Lorenz Kuske; Stefan Zeuzem; W Peter Hofmann; Robert J de Knegt; Bettina E Hansen; Harry L A Janssen
Journal:  JAMA       Date:  2012-12-26       Impact factor: 56.272

10.  The natural history of hepatitis C virus (HCV) infection.

Authors:  Stephen L Chen; Timothy R Morgan
Journal:  Int J Med Sci       Date:  2006-04-01       Impact factor: 3.738

View more
  2 in total

1.  Advanced liver fibrosis and care continuum in emergency department patients with chronic hepatitis C.

Authors:  Yu-Hsiang Hsieh; Danielle Signer; Anuj V Patel; Valentina Viertel; Mustapha Saheed; Risha Irvin; Mark S Sulkowski; David L Thomas; Richard E Rothman
Journal:  Am J Emerg Med       Date:  2018-08-29       Impact factor: 2.469

2.  Hepatitis C Virus Incidence in a Cohort in Medication-Assisted Treatment for Opioid Use Disorder in New York City.

Authors:  Ashly E Jordan; Charles M Cleland; Katarzyna Wyka; Bruce R Schackman; David C Perlman; Denis Nash
Journal:  J Infect Dis       Date:  2020-09-02       Impact factor: 5.226

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.